Phase II study of oral fludarabine in combination with rituximab for relapsed indolent b-cell non-hodgkin lymphoma

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1951-1956

  Tobinai, Kensei ^a   Ishizawa, Ken ichi ^b   Ogura, Michinori ^c   Itoh, Kuniaki ^d   Morishima, Yasuo ^e   Ando, Kiyoshi ^f   Taniwaki, Masafumi ^g   Watanabe, Takashi ^a   Yamamoto, Joji ^b   Uchida, Toshiki ^c   Nakata, Masanobu ^d,l   Terauchi, Takashi ^h   Nawano, Shigeru ^d,m   Matsusako, Masaki ⁱ   Hayashi, Masaki ^j,n   Hotta, Tomomitsu ^k  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^h NATIONAL CANCER CENTER   (Japan)

ⁱ ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^j Bayer HealthCare ^*  (Japan)

^k NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^l SAPPORO HOKUYU HOSPITAL   (Japan)

^m International University of Health and Welfare Mita Hospital   (Japan)

ⁿ Nakagami Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE PHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; B CELL LYMPHOMA; BACKACHE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROPENIA; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERURICEMIA; HYPOPROTEINEMIA; IMMUNOPATHOLOGY; INFLUENZA; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MALE; MONOCYTOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TREATMENT OUTCOME; VIDARABINE;

EID: 70349591632     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01247.x     Document Type: Article

References (34)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993, 20:75-88.
2. Schulz H, Bohlius JF, Trelle S. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706-14.
3. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711-16.
4. Hiddemann W, Kneba M, Dreyling M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-32.
5. Ogura M, Morishima Y, Kagami Y. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 2006, 97:305-12.
6. Marcus R, Imrie K, Solal-Celigny P. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008, 26:4579-86.
7. Itoh K, Igarashi T, Ogura M. Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-NHL: 7-year follow-up results. J Clin Oncol 2008, Suppl:482s. Abstract 8616
8. Hochster HS, Kim KM, Green MD. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992, 10:28-32.
9. Redman JR, Cabanillas F, Velasquez WS. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992, 10:790-4.
10. Klasa RJ, Meyer RM, Shustik C. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol 2002, 20:4649-54.
11. Flinn IW, Byrd JC, Morrison C. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000, 96:71-5.
12. McLaughlin P, Hagemeister FB, Romaguera JE. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996, 14:1262-8.
13. Tsimberidou AM, McLaughlin P, Younes A. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 2002, 100:4351-7.
14. Hochster HS, Oken MM, Winter JN. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up - a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000, 18:987-94.
15. Hochster H, Weller E, Kuzel T. Increased mortality associated with higher dose cyclophosphamide plus fludarabine in advanced stage indolent lymphoma patients treated on E1496, an ECOG and CALGB study. Proc Am Soc Clin Oncol 2002, 21:282a.
16. Tsimberidou A-M, Younes A, Romaguera J. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 2005, 104:345-53.
17. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001, 7:709-23.
18. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 2000, 20:2961-6.
19. Di Gaetano N, Xiao Y, Erba E. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001, 114:800-9.
20. Demidem A, Lam T, Alas S. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177-86.
21. Czuczman MS, Koryzna A, Mohr A. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005, 23:694-704.
22. Ogawa Y, Hotta T, Tobinai K. Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. Ann Oncol 2006, 17:330-3.
23. Tobinai K, Watanabe T, Ogura M. Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 2006, 24:174-80.
24. Harris NL, Jaffe ES, Diebold J. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-49.
25. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-55.
26. Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999, 17:1244-53.
27. Solal-Celigny P, Roy P, Colombat P. Follicular lymphoma international prognostic index. Blood 2004, 104:1258-65.
28. Ogura M, Morishima Y, Kobayashi Y. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol 2004, 80:267-77.
29. McLaughlin P, Grillo-López AJ, Link BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-33.
30. Igarashi T, Kobayashi Y, Ogura M. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002, 13:928-43.
31. Witzig TE, Gordon LI, Cabanillas F. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:2453-63.
32. Rummel MJ, Al-Batran SE, Kim SZ. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-9.
33. Robinson KS, Williams ME, van der Jagt RH. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4473-9.
34. Nitta E, Izutsu K, Sato T. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007, 18:364-9.